NCT05313555

Brief Summary

The purpose of this trial is to determine the safety of ultraviolet light (UV-C) irradiation as a method to sanitize hands instead of chemical-based sanitizers. Eligible participants will be enrolled and receive treatment with the Violet UV-C device or UV-B. Punch biopsies will be performed following UV exposure to quantify any changes in cellular and molecular properties of the tissue.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at P25-P50 for not_applicable healthy-volunteers

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 28, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 6, 2022

Completed
13 days until next milestone

Study Start

First participant enrolled

April 19, 2022

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 12, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 12, 2022

Completed
3.7 years until next milestone

Results Posted

Study results publicly available

May 28, 2026

Completed
Last Updated

May 28, 2026

Status Verified

July 1, 2025

Enrollment Period

5 months

First QC Date

March 28, 2022

Results QC Date

May 2, 2026

Last Update Submit

May 2, 2026

Conditions

Keywords

ultraviolet lightlight skinskin changeshealthy volunteers

Outcome Measures

Primary Outcomes (1)

  • Deoxyribonucleic Acid (DNA) Damage in the Form of DNA Base Pair Dimers Measured by Immunohistochemistry Microscopy With Statistical Analysis.

    Day 1 (visit 1 after light therapy)

Study Arms (5)

Ultraviolet lights (UV-B)

ACTIVE COMPARATOR
Device: Ultraviolet Light (UV-B)

Ultraviolet lights (UV-C) - 1 use

EXPERIMENTAL
Device: Ultraviolet lights (UV-C) - 1 cycle

Ultraviolet lights (UV-C) - 10 uses

EXPERIMENTAL
Device: Ultraviolet lights (UV-C) - 10 cycles

Ultraviolet lights (UV-C) - 15 uses

EXPERIMENTAL
Device: Ultraviolet lights (UV-C) - 15 cycles

Ultraviolet lights (UV-C) - 25 uses

EXPERIMENTAL
Device: Ultraviolet lights (UV-C) - 25 cycles

Interventions

This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.

Ultraviolet lights (UV-B)

Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will be exposed to 1 cycle of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.

Also known as: Violet UV-C Light, Care222
Ultraviolet lights (UV-C) - 1 use

Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will be exposed to 10 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.

Ultraviolet lights (UV-C) - 10 uses

Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will be exposed to 15 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.

Ultraviolet lights (UV-C) - 15 uses

Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will be exposed to 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.

Ultraviolet lights (UV-C) - 25 uses

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Good general health
  • Type 1 or type 2 skin (lightly colored skin)
  • No history of skin disorders, disease states or physical conditions which would impair evaluation of the test sites
  • Willingness and ability to follow the protocol
  • No use of lotion or hand sanitizer 3 hours before the experiment

You may not qualify if:

  • Has received an experimental drug or used an experimental device in the 30 days prior to admission to the study
  • Undergoing treatment or taking medication that increases sun sensitivity
  • History of keloids
  • History of sensitivity to lidocaine or epinephrine
  • Pregnant or nursing women, pregnancy status will be self-reported, women unsure of their pregnancy status will be excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Results Point of Contact

Title
Gary Fisher, PhD
Organization
University of Michigan

Study Officials

  • Gary Fisher, PhD

    University of Michigan

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants were randomized into UV-B and UV-C groups. Those who were randomized into the UV-C group were then able to choose how many cycles of UV-C exposure they would receive.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 28, 2022

First Posted

April 6, 2022

Study Start

April 19, 2022

Primary Completion

September 12, 2022

Study Completion

September 12, 2022

Last Updated

May 28, 2026

Results First Posted

May 28, 2026

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations